To print: Select File and then Print from your browser's menu

Title: Growth Hormone Increase Bone Content In Osteoporotic Postmenopausal Women

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12619921&dopt=Abstract

J Bone Miner Res 2003 Mar;18:3:393-405. "Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial"
03/12/2003 11:55:25 AM
By Harvey McConnell

Growth hormone treatment combined with hormone replacement therapy, calcium and vitamin D appears to increase bone mineral content up to 14% in postmenopausal women with osteoporosis. In a long term Swedish study, 80 osteoporotic postmenopausal women, aged between 50 and 70, who were using oestrogen therapy (HRT), were randomised to receive either recombinant human growth hormone (GH), 1.0 U or 2.5 U/day, subcutaneous, or placebo. Calcium (750 mg) and vitamin D (400 U) were given to all patients as well. The study was based at the Department of Medicine, Sahlgrenska University Hospital, Goteborg, Sweden. The first study arm was double-blinded and lasted for 18 months, when women in the placebo group stopped their daily injections. However, women in both GH dosage groups continued treatment for a total of three years and were then followed-up for five years. Bone mineral density and bone mineral content were measured with dual-energy X-ray absorptiometry. At the end of the first arm, the researchers found that total body bone mineral content was highest in the GH 2.5 U group. At 3 years, when GH was discontinued, total body and femoral neck bone mineral content had increased in both GH-treated groups, and differences were not significant. At the fourth year of follow-up, total body boner mineral content had increased 5% and lumbar spine bone mineral content increased 14% among women who received GH 2.5 U, and compared with placebo. Femoral neck bone mineral density increased 5% and bone mineral content 13% for women taking GH 2.5 U compared with those taking GH 1.0 U. At follow-up after five years no differences in bone mineral density or bone mineral content were seen between groups. Bone markers showed increased turnover. Three women in the GH 1.0 U group experienced fractures. Side effects were rare over the trial period, and none of the women taking part dropped out. The clinicians concluded that there seems to be a delayed, extended, and dose-dependent effect of GH on bone. For these reasons, GH could be used as an anabolic agent in osteoporosis.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12619921&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.